{"public_id":"cl_a339f0ed694b234b7cbd9b5eaac90eb2","status":"active","superseded_by_public_id":null,"corpus_id":73316763,"text":"Quinolone resistance was high in these commensal Escherichia coli isolates, reaching 32% for nalidixic acid and 12% for ciprofloxacin.","confidence":0.98,"paper":{"corpus_id":73316763,"title":"Niveles de resistencia a quinolonas y otros antimicrobianos en cepas de Escherichia coli comensales en niños de la zona periurbana de Lima, Perú","url":"https://sah.borca.ai/papers/73316763"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_5742a04eeb58fc7302b50c99a1c9f573","name":"nalidixic acid","description":"A quinolone antimicrobial used here to assess resistance.","types":["antimicrobial"],"url":"https://sah.borca.ai/concepts/co_5742a04eeb58fc7302b50c99a1c9f573"},{"public_id":"co_61ef0f39df7d6f01486a908638cc4aba","name":"ciprofloxacin","description":"A fluoroquinolone antimicrobial used here to assess resistance.","types":["antimicrobial"],"url":"https://sah.borca.ai/concepts/co_61ef0f39df7d6f01486a908638cc4aba"},{"public_id":"co_c6f7640b6c0dc56af5835771c41a0793","name":"quinolones","description":"A class of antimicrobial agents that includes nalidixic acid and ciprofloxacin.","types":["antimicrobial class"],"url":"https://sah.borca.ai/concepts/co_c6f7640b6c0dc56af5835771c41a0793"},{"public_id":"co_f2fe9b242214e31fe62b1d3ec20a342f","name":"commensal Escherichia coli fecal isolates","description":"Non-pathogenic Escherichia coli strains isolated from fecal samples in the studied children.","types":["biological sample","microbial isolate"],"url":"https://sah.borca.ai/concepts/co_f2fe9b242214e31fe62b1d3ec20a342f"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_a339f0ed694b234b7cbd9b5eaac90eb2"}